Watch FATE. Know when insiders buy.
One email the day a filing lands. Free.
FATE
FATE THERAPEUTICS INC
2.31
−0.02 −0.86%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
26
FLAG · shorts 26
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $276.8MP/E —DIV YIELD —FCF YIELD -38.16%REV TTM $6.5M −23.4%NET INCOME −$126MNET CASH $13.9M52W 0.95 – 3.11SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.1M | +9.2% | — | −$31.1M | −$30.2M | — | -0.25 | −$23.4M | $80K | −$23.5M | Aug 13 |
| Q1 2026 · Mar 31 | $1.3M | −20.3% | — | −$33M | −$31.2M | — | -0.26 | −$30.8M | $239K | −$31.1M | Aug 13 |
| Q4 2025 · Dec 31derived | $1.4M | −26.4% | — | −$34.7M | −$32.4M | — | -0.27 | −$23.3M | $1.2M | −$24.5M | Feb 26 |
| Q3 2025 · Sep 30 | $1.7M | −43.4% | — | −$34.7M | −$32.3M | — | -0.27 | −$24.4M | $2.2M | −$26.6M | Nov 13 |
| Q2 2025 · Jun 30 | $1.9M | −71.8% | — | −$37M | −$34.1M | — | -0.29 | −$24.6M | $1.4M | −$25.9M | Aug 13 |
| Q1 2025 · Mar 31 | $1.6M | −15.4% | — | −$41.3M | −$37.6M | — | -0.32 | −$33.8M | $1.2M | −$35M | Aug 13 |
| Q4 2024 · Dec 31derived | $1.9M | +11.0% | — | −$61.7M | −$52.2M | — | -0.45 | −$27.8M | $98K | −$27.9M | Feb 26 |
| Q3 2024 · Sep 30 | $3.1M | +58.1% | — | −$52.4M | −$47.7M | — | -0.40 | −$29.4M | $495K | −$29.9M | Nov 13 |
| Q2 2024 · Jun 30 | $6.8M | — | — | −$45.1M | −$38.4M | — | -0.33 | −$32.3M | $51K | −$32.4M | Nov 13 |
| Q1 2024 · Mar 31 | $1.9M | — | — | −$51.1M | −$48M | — | -0.47 | −$33.4M | $86K | −$33.4M | Nov 13 |
| Q4 2023 · Dec 31derived | $1.7M | — | — | −$48.1M | −$44.1M | — | -0.45 | −$36.6M | $181K | −$36.8M | Mar 5 |
| Q3 2023 · Sep 30 | $1.9M | — | — | −$51.3M | −$45.2M | — | -0.46 | −$38.3M | $565K | −$38.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $6.6M | — | −$147.7M | −$136.3M | -2051.1% | -1.15 | −$106.1M | $6M | −$112M | — | — |
| FY2024 · to Dec 31 | $13.6M | — | −$210.3M | −$186.3M | -1366.5% | -1.64 | −$122.9M | $730K | −$123.6M | — | — |
| FY2023 · to Dec 31 | $63.5M | — | −$190.5M | −$160.9M | -253.3% | -1.64 | −$132.3M | $6.2M | −$138.4M | — | — |
| FY2022 · to Dec 31 | $96.3M | — | −$308.4M | −$281.7M | -292.5% | -2.91 | −$248.2M | $35.6M | −$283.8M | — | — |
| FY2021 · to Dec 31 | $55.8M | — | −$217M | −$212.2M | -379.9% | -2.24 | −$162.9M | $50.7M | −$213.6M | — | — |
| FY2020 · to Dec 31 | $31.4M | — | −$128.1M | −$173.4M | -551.6% | -2.10 | −$39.2M | $4.9M | −$44.2M | — | — |
Every number comes from FATE THERAPEUTICS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.